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C4 (cobalt dichloride-N-acetylcysteine [1% CoCl2 :2% NAC]) is a novel magnetic resonance imaging contrast marker that facilitates
visualization of implanted radioactive seeds in cancer brachytherapy. We evaluated the toxicity of C4. Rats were assigned to control
(0% CoCl2 :NAC), low-dose (0.1% CoCl2 :2% NAC), reference-dose (C4), and high-dose (10% CoCl2 :2% NAC) groups. Agent was
injected into the left quadriceps femoris muscle of the rats. Endpoints were organ and body weights, hematology, and serum
chemistry and histopathologic changes of tissues at 48 hours and 28 and 63 days after dosing. Student’s 𝑡 tests were used. No
abnormalities in clinical signs, terminal body and organ weights, or hematologic and serum chemistry were noted, and no gross
or histopathologic lesions of systemic tissue toxicity were found in any treatment group at any time point studied. At the site
of injection, concentration-dependent acute responses were observed in all treatment groups at 48 hours after dosing and were
recovered by 28 days. No myofiber degeneration or necrosis was observed at 28 or 63 days in any group. In conclusion, a single
intramuscular dose of C4 produced no acute or chronic systemic toxicity or inflammation in rats, suggesting that C4 may be
toxicologically safe for clinical use in cancer brachytherapy.

1. Introduction
The current standard of care after brachytherapy for localized
prostate cancer includes an image-guided quality assurance
check of the radioactive seed placement and anticipated dose
distribution. Historically the imaging technique used for this
purpose is computed tomography (CT). Although CT can
effectively visualize the seeds, it is less successful for visualizing soft tissues such as the prostate. Magnetic resonance
imaging (MRI), on the other hand, is ideal for visualizing
soft tissues [1, 2] but requires a positive-contrast marker
to identify the seeds [3]; nevertheless, MRI is increasingly

being viewed as an excellent imaging tool for posttreatment
quality assurance [4, 5]. One positive-contrast marker under
T1-weighted sequence scanning being developed for this
purpose is C4, a complex of cobalt dichloride and N-acetylcysteine (CoCl2 :NAC) that is encapsulated within a permanently implantable device [3]. Previous studies have
shown that C4 does not affect anisotropy or volumetric
dosimetry when placed adjacent to radioactive seeds, nor
does it alter the T1 positive-contrast signal after exposure to
high doses of radiation [6]. C4 further has a complexation
rate of >90%, is stable in solution, and remains stable
upon exposure to human plasma at physiological pH and

2
temperature (Supplemental Tables 1 and 2). A study of
the pharmacokinetics, biodistribution, and acute toxicity of
C4 demonstrated rapid, dual-route elimination and lack of
toxicity after injection of the C4 solution into the prostate
and periprostatic tissues [7]. However, some evidence of
intraprostatic inflammation was observed on histopathologic evaluation; whether that inflammation was related
to the surgical procedure or to C4 was unclear. Further,
whether leakage of the C4 solution from the capsules after
prostate brachytherapy would potentiate systemic inflammatory effects or produce acute or chronic toxicity is unknown.
Hence the purpose of this study was to evaluate the potential
inflammatory toxicity of C4 in the target organs and systemically. An experimental model in which C4 is injected into
the quadriceps femoris muscle of rats, which would allow
evaluation of local tissue tolerance and recovery from of
any damage, and accurate assessment of local and systemic
inflammation was used.

2. Materials and Methods
2.1. C4 Solutions. Solutions at each dose level were prepared within 1 week of administration under a standard
operating procedure in which CoCl2 :NAC is prepared from
cobalt chloride hexahydrate (CoCl2 ∙ 6H2 O; Sigma), Nacetylcysteine (C5 H9 NO3 S; Sigma), and ultrapure, filtered,
double-deionized water (Milli-Q, Millipore). Solutions were
stored at 5 ± 3∘ C and protected from light until administration. At the prescribed injection times, solutions were
warmed to room temperature and transferred to the animal
facility while still protected from light. Solutions were analyzed for total cobalt content both before and after dosing by
inductively coupled plasma mass spectrometry at A&B Labs
(Houston, TX).
2.2. Animals. Sixty male Sprague-Dawley rats, aged 12-13
weeks and weighing 300–450 g, were supplied by Charles
River Laboratories. This species has been accepted to support
studies of compounds intended to be used in humans.
Procedures for animal housing and care were carried out
in accordance with the Animal Welfare Act as amended in
the recommendations and guidelines of the Public Health
Service, the US Department of Agriculture, the Association
for Assessment and Accreditation of Laboratory Animal
Care International, and Institutional Animal Care and Use
Committee of UT MD Anderson Cancer Center. Environmental conditions were within specified limits in at
least 90% of scheduled observations. Rats were housed up
to 3 per cage with bedding or cage board (rather than
cedar or pine chips), and cages were sanitized regularly.
No known contaminants that could affect the results of
the study were present in the bedding. The rats were fed
a commercial, dry rodent chow ad libitum, and water was
also given ad libitum. All rats were quarantined for at least
3 days before dosing, and no prophylactic or therapeutic
treatments were given during the quarantine period. Rats
were identified individually, by cage, and by treatment
group.
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2.3. Animal Treatments. Rats were assigned to one of four
dosage groups (15 rats/dose group): control (0% CoCl2 :NAC),
low dose (0.1% CoCl2 :2% NAC), mid- or reference dose (1%
CoCl2 :2% NAC; this is the solution used in the MRI-marker
medical device), or high dose (10% CoCl2 :2% NAC). These
concentrations were based on the concentrations contained
within the reference medical device (1% CoCl2 ∙ 6H2 O),
bracketed by one higher level (10% CoCl2 ∙ 6H2 O) and one
lower level (0.1% CoCl2 ∙ 6H2 O). All solutions contained
2% NAC. The solutions were given in 9-𝜇L aliquots with
a Hamilton 1700 series gas-tight 25 𝜇L syringe with a 27
gauge/0.5 inch needle by intramuscular (i.m.) injection into
the middle of the left hind limb quadriceps femoris. Rats were
anesthetized and maintained with isoflurane inhalation to
prevent trauma to the muscle during the injection. Once the
rats were anesthetized and immediately before the injection,
hair around the injection site area was clipped and the
injection site wiped with 70% alcohol. Unless otherwise
noted, the rats were injected in the order listed above (control,
low dose, reference dose, and high dose). The injection sites
were circled immediately after the injection with a permanent
marker.
2.4. Clinical Observations, Necropsy, and Tissue Sampling.
Rats were observed for clinical signs daily and weighed twice
weekly. At 2 days (48 hours), 28 days, or 63 days after the
injection, 5 rats from each dose group (3 experimental and
1 control) were euthanized with carbon dioxide, weighed,
exsanguinated, and subjected to necropsy. Blood samples
were collected immediately after euthanasia via cardiac puncture for hematology and serum chemistry analyses from all
4 groups at each of the 3 time points. All rats were weighed
just before terminal blood collection. At necropsy, the liver,
kidney, and spleen were weighed, all organs were examined
grossly, and tissue samples described in Supplemental Table 3
were collected in 10% neutral buffered formalin for fixation.
In addition, the entire quadriceps femoris muscle, the target
tissue with the site of injection, from the treated left hind
limb (containing the marked area of injection site), and the
untreated right hind limb from all animals (control and 3 dose
groups at 48 hours, 28 days, and 63 days after treatment) were
collected in formalin for fixation, histologic processing, and
microscopic examination. All remaining tissues from the 63day time point dose groups were preserved in 10% neutral
buffered formalin and archived. A veterinary pathologist
examined all animals at necropsy and recorded the presence
of tissue changes.
2.5. Blood Sample Processing and Analysis. Blood samples
collected in microtubes with serum separator were allowed to
clot for 30 minutes after collection and were then centrifuged
for 2 minutes at 17,000 rpm for isolating the blood serum
that was processed for serum chemistry analysis. For hematologic analyses, blood samples were collected in microtubes
containing ethylenediaminetetraacetic acid (EDTA); for the
complete blood cell count analysis, blood smears were stained
with Diff-Quik. Complete blood cell count analysis was
performed with a Cobas Integra 400 Plus instrument (Roche)
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and serum chemistry measurements with an Advia 120
instrument (Siemens AG).
2.6. Tissue Processing for Histologic Analysis. After fixation,
all tissues (Tables 1 and 2) from the control and high-dose
groups euthanized at 48 hours and 28 days after treatment
were processed, embedded in paraffin blocks, and cut into
4-𝜇m thick sections that were mounted on glass slides and
stained with hematoxylin-and-eosin (H&E) for microscopic
examination. The entire left quadriceps femoris muscle,
including the injection site, from all rats was cut in multiple
slices at 3-mm intervals for similar histologic preparation. All
histologic sections of these organs, including the observed
gross lesions, were examined and evaluated microscopically by a veterinary pathologist. All histologic sections of
quadriceps femoris muscle from treated left hind limbs were
scanned with Aperio, and the extent of lesions at the site of
i.m. injection was measured in all sections.
2.7. Statistical Analysis. Each experiment was repeated at least
three times. Unless otherwise noted, data are presented as
means and ranges, and Student’s 𝑡 tests (unpaired, unequal
variance) were used to compare two groups of independent
samples for body weight, absolute and relative organ weights,
and blood hematologic or serum chemistry values. A P value
of <0.05 was considered to indicate statistically significant
differences.

3. Results
3.1. Clinical Observations. All animals survived until their
scheduled termination dates. No adverse clinical signs or
abnormalities in body weight or in absolute or relative
organ weights were noted, and no significant hematologic
abnormalities were found (Table 1). Although neutrophil and
monocyte counts were slightly elevated in the treatment
groups relative to the control group at 48 hours, the increased
values remained within the normal reference range, and these
values had recovered to control levels by 28 days and 63
days after injection (Table 1). This transient elevation most
likely reflected local injection-related trauma resulting in
local inflammation and necrosis of skeletal myofibers; thus
we did not consider this an adverse effect but rather a normal
physiologic response. The slight decrease in lymphocytes
counts in the high-dose group versus control group at 48
hours after injection also remained within the normal reference range and likely reflected a stress response rather than
a treatment-related adverse effect. In terms of statistically
significant differences, the mean corpuscular volume of red
blood cells had dropped at 48 hours in the high-dose group,
and mean corpuscular hemoglobin concentrations had risen
in the low-dose and reference-dose groups at 63 days relative
to the control-group values (Table 1). None of these findings
indicate a clinically meaningful adverse effect, because all
differences remained within the normal reference range and
the mean corpuscular volume had returned to control levels
at 28 days after dosing.
Similarly, no significant abnormalities of serum chemistry tests were noted (Table 2). Mild elevations in aspartate
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transaminase (AST) and alkaline aminotransferase (ALT)
were observed at all 3 time points in some groups, but
they were not dose-related and the liver, heart and kidney
were normal histologically. Rather, these slight variations in
values reflected the combination of minimal injury to skeletal
muscle and false increases from slight hemolysis of blood
samples. Other statistically significant differences were noted
in the increase of globulin level (P=0.014), and decrease
of AST (P=0.05) and ALT (P=0.017) levels at 28 days in
the reference group relative to the control group (Table 2),
but these findings did not confirm a dose-related trend
change and therefore were not considered clinically adverse
effects.
3.2. Pathological Findings. No gross pathologic lesions were
found during necropsy, and no histopathologic evidence
of acute or chronic systemic toxicity or inflammation was
observed in any of the tissues examined (including brain,
spinal cord, lung, heart, liver, kidney, and spleen) from the
control and high-dose groups at 48 hours or 28 days after i.m.
injection of CoCl2 :NAC.
Acute dose-related injury of transient focal myotoxicity
at the injection site was noted in all three treatment groups
at 48 hours after injection (Figures 1(a)–1(c)). Areas of
affected muscle tissue were typically about 1 mm × 4 mm
and showed acute degeneration and necrosis of myofibers
of skeletal muscle. Four of the five mice in the referencedose group and all five of the mice in the high-dose group
were affected with this lesion. Moreover, the extent of the
degeneration and necrosis of myofibers (measured with an
Aperio whole-slide digital image scanner) was considerably
greater in the high-dose group (average of the affected
muscle area: 5,080,354 𝜇m2 ) than in the reference-dose group
(average of the affected muscle area: 1,873,015 𝜇m2 ). Acute
granulomatous inflammation with infiltration of neutrophils
and macrophages at the injection site was observed in control
and treated animals at 48 hours, and this was consistent with
normal tissue reaction to injected material and early healing
response. The severity of inflammation at the site of injection
was associated with the dose level, indicating an acute local
toxic effect of C4 to skeletal muscle (Figures 1(a)–1(c)).
In the chronic stages of treatment, at 28 and 63 days
after injection, no degenerative or necrotic lesions were
observed in the left quadriceps femoris in any animals from
the control or treated groups (Figures 1(d)–1(f)). Indeed,
skeletal muscle myofibers at the injection site had largely
returned to normal by Day 28, albeit with scattered very small
foci of macrophages (histiocytosis) and areas of regenerated
myofibers, indicating resolution of the muscle lesions and
associated minimal inflammation at the site of injection.
No evidence of ongoing treatment-related tissue injury was
noted at 63 days after treatment, when no microscopic or
macroscopic lesions were observed in any of the control
or treated groups (Figures 1(g)–1(i)). Further progression of
tissue healing was reflected in the presence of smaller size
regenerated myofibers surrounded by minimal interstitial
fibrous tissue and occasional small foci of infiltrated histiocytes at the injection site.

MCHC, g/dL
30.8 (29.1-32.6)
30.9 (29.5-32.1)
30.1 (29.4-30.6)
30.9 (30.2-31.7)
30.5 (30.3-30.7)
30.5 (30.1-30.9)
31.1 (29.8-31.7)
30.6 (29.8-31.4)
30.9 (30.6-31.4)
31.9∗ (31.0-32.5)
32.2∗ (32-32.5)
31.4 (30.1-32.3)

MCV, fL

61.7 (57.8-64.0)
61.1 (57.1-63.3)
61.3 (57.8-62.9)
58.5∗ (56.8-60.0)

58.7 (58-59.6)
59.3 (56.5-62.0)
58.8 (57.3-59.8)
58.8 (56.5-60.1)

58.8 (57.7-61.2)
58.9 (57.0-60.5)
58.7 (57.2-60.7)
57.8 (55.8-61.1)

1.65 (0.95-2.29)
2.0 (1.16-2.52)
1.8 (1.06-2.68)
1.6 (1.0-2.38)

2.21 (1.03-2.87)
2.5 (1.31-3.95)
2.3 (1.08-3.57)
2.7 (2.07-3.20)

2.3 (1.04-2.99)
3.1 (1.67-4.63)
3.1 (0.9-5.27)
3.5 (2.15-4.64)

15 (8.9-20.3)
16.2 (12.0-19.4)
15.7 (10.1-24.2)
12.6 (6.9-16.8)

22.1 (11.6-28.4)
21.6 (15-34.4)
24.2 (13.1-37.1)
23.1 (20.1-26.8)

18.4 (10.4-24.9)
21.6 (15.3-27.9)
20.1 (11.2-26.7)
26.6 (19.0-34.4)

Neutrophils
%
×103 /𝜇L

Data are shown as mean (range).∗Significantly different from control at P< 0.05.
Control, 0% CoCl2 :NAC; Low dose, 0.1% CoCl2 :2% NAC; Ref[erence] dose 1% CoCl2 :2% NAC; High dose, 10% CoCl2 :2% NAC.
MCV, mean corpuscular volume (in femtoliters); MCHC, mean corpuscular hemoglobin concentration.

Time after Injection and
Treatment Group
Day 2
Control
Low dose
Ref dose
High dose
Day 28
Control
Low dose
Ref dose
High dose
Day 63
Control
Low dose
Ref dose
High dose

Table 1: Hematologic findings.

0.22 (0.16-0.37)
0.26 (0.19-0.35)
0.23 (0.11-0.34)
0.25 (0.09-0.38)

0.22 (0.16-0.3)
0.27 (0.18-0.35)
0.31 (0.16-0.56)
0.31 (0.20-0.53)

0.27 (0.10-0.43)
0.33 (0.25-0.56)
0.33 (0.09-0.54)
0.4 (0.27-0.87)

%

2 (1.3-3.3)
2.2 (1.5-3.1)
2.0 (1.3-3.2)
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8.3 (6.23-13.28)
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10.5 (8.43-15.38)
10.1 (6.84-15.13)
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78.6 (69.6-85.3)
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71.6 (55.6-80)
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0.34 (0.32-0.36)
0.33 (0.31-0.35)
0.32 (0.30-0.35)
0.31 (0.26-0.33)

19.9 (18.8-21.4)
20.7 (17.6-23.6)
19.6 (17.9-21.7)
18.4 (16.9-19.5)

17.9 (16.2-19.5)
20.1 (17.3-24.6)
12.2 (15.8-20.2)
19.3 (17.4-21.4)

<0.1 (<0.01)
0.32 (0.28-0.35)
<0.01 (<0.01) 0.31 (0.27-0.34)
<0.01 (<0.01) 0.32 (0.29-0.37)
<0.01 (<0.01) 0.31 (0.31->0.69)†

0.1 (0.1)
0.1 (0.1)
0.1 (0.1)
0.1 (0.1)

15.80 (14.2-16.7)
16.40 (14.8-18.8)
16.9 (15.9-19.6)
16.1 (14.0-18.8)

0.3 (0.28-0.32)
0.3 (0.28-0.35)
0.27 (0.24-0.30)
0.29 (0.25-0.34)

0.1 (0.1)
0.1 (0.1)
0.1 (0.1)
0.1 (0.1)

mg/dL

Creatinine,

135 (68-325)
142 (84-266)
247 (180-336)
136 (67-232)

– (154->3836)†
– (123->964)†
– (56->2530)†
– (59->7000)†

219 (122-445)
283 (121-869)
199 (68-491)
132 (70-318)

Aspartate
Transaminase,
mg/dL

141 (41-473)
113 (52-239)
193 (153-230)
114 (39-233)

– (48->4070)†
– (65->921)†
– (45->3030)†
– (45->7000)†

175 (54-441)
266 (78-921)
173 (44-428)
99 (44-244)

Alkaline Aminotransferase,
IU/L

Table 2: Clinical chemistry findings.
Blood Urea
Nitrogen,
mg/dL

Data are shown as mean (range). ∗Significantly different from control at 푃 < 0.05. †Out of range because of hemolysis.
Control, 0% CoCl2 :NAC; Low dose, 0.1% CoCl2 :2% NAC; Ref[erence] dose, 1% CoCl2 :2% NAC; High dose, 10% CoCL2 : 2% NAC.

Day 2
Control
Low dose
Ref dose
High dose
Day 28
Control
Low dose
Ref dose
High dose
Day 63
Control
Low dose
Ref dose
High dose

Time after Injection and Treatment
Group

Total
Bilirubin,
mg/dL

141 (111-195)
165 (127-206)
149 (89-235)
115 (100-135)

186 (141-252)
202 (173-258)
140∗ (128-163)
210 (131-287)

168 (98-228)
208 (132-306)
201 (175-239)
167 (144-230)

Alkaline
Phosphatase,
IU/L

6.89 (6.56-7.21)
7.01 (6.69-7.70)
6.57 (6.26-7.10)
6.73 (6.27-7.33)

6.3 (5.98-6.95)
6.36 (5.91-6.74)
6.68 (6.34-6.83
6.87 (6.39-7.87)

6.18 (5.58-6.59)
6.23 (5.83-6.74)
6.1 (5.88-6.28)
6.21 (5.82-6.44)

g/dL

Total Protein,

4.33 (4.21-4.44)
4.40 (4.14-4.90)
4.22 (3.98-4.58)
4.16 (3.89-4.57)

4.26 (4.17-4.47)
4.18 (3.95-4.36)
4.19 (4.04-4.31)
4.32 (4.11-4.60)

4.21 (4.01-4.60)
4.16 (4.11-4.22)
4.2 (4.09-4.35)
4.04 (3.87-4.16)

g/dL

Albumin,

2.56 (2.21-2.88)
2.61 (2.48-2.80)
2.36 (2.00-2.52)
2.57 (2.38-3.07)

2.04 (1.78-2.48)
2.17 (1.76-2.66)
2.49∗ (2.30-2.65)
2.51 (2.13-3.27)

1.97 (1.57-2.30)
2.07 (1.72-2.61)
1.9 (1.53-2.18)
2.17 (1.95-2.45)

g/dL

Globulin,
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0% CoCl 2:NAC

Day 63

Day 63

Day 63

(g)

20x
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20x
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40x
 m

(h)

(i)

Figure 1: Histopathological changes of skeletal muscle at the site of C4 (CoCl2 :NAC) injection. A volume of nine microliters of CoCl2 :NAC
at various concentrations (0% CoCl2:NAC [control], 1% CoCl2:2% NAC [mid- or reference dose], and 10% CoCl2:2% NAC [high dose])
was injected intramuscular into the middle region of the left hind limb quadriceps femoris muscle of male Sprague-Dawley rats. Images of
H&E stained tissue sections at 20x and 40x magnification. (a)–(c) Images show mild inflammation (arrow) in control animals (a) and acute
degeneration and necrosis of myofibers with granulomatous inflammation at the site of intramuscular injection (arrows) in the mid- and
high-dose groups ((b) and (c), respectively), at 48 hours after treatment. (d)–(f) Images show minimal edema with occasional degenerated
myofibers (arrow) in control (d) and middose group (e) animals, which is associated with focal mild lymphohistiocytic inflammation (arrow)
and myofiber regeneration in the high-dose group (f), at 28 days after treatment. (g)–(i) Images reveal presence of rare small foci of histiocytic
inflammation (arrow) similar in control and treated groups of animals ((g), (h), and (i)), and areas of normally regenerated myofibers
surrounded by minimal interstitial fibrosis in the mid- and high-dose groups ((h) and (i), respectively), at 63 days after treatment.

4. Discussion
The results of this study of Sprague-Dawley rats indicated
that a single intramuscular injection, in the middle of the
quadriceps femoris muscle, of up to 10% CoCl2 :2% NAC
produced no significant treatment-related adverse clinical
signs, no changes in body or organ weights, and no significant changes in hematologic or serum chemistry values.
Similarly, postmortem pathological investigations revealed
no gross or histopathologic evidence of acute or chronic
systemic toxicity or inflammation. At 48 hours after i.m.
injection, minor acute hematologic changes were noted in
neutrophil, monocyte, and lymphocyte numbers, and mild
focal myotoxicity manifested with acute degeneration and
necrosis of myofibers associated with acute granulomatous

inflammation at the injection site. Since these lesions healed
and returned to normal skeletal muscle at 28 and 63 days after
i.m. injection, these changes are considered to be a normal
physiologic healing response to transient local acute muscle
injury.
MRI provides superb anatomic resolution [8]; moreover,
it can also visualize physiological changes in the tumor microenvironment or organ perfusion via dynamic contrastenhanced MRI (DCE-MRI) [9, 10], which requires intravenous administration of gadolinium-based MR contrast
agents [11]. Such agents are routinely used in clinical practice and were thought to be relatively safe [12]. However,
gadolinium-enhanced MRI was recently linked with nephrogenic systemic fibrosis, a severe, potentially fatal adverse
reaction, in some patients with renal impairment. This
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syndrome is a rare idiopathic skin condition, accompanied by
pain and loss of mobility with involvement of the kidney and
other organs such as lung, heart, liver, and diaphragm [12–
16]. An alternative to gadolinium-based agents, C4, includes
ionized cobalt [Co2+ , or Co(II)], which can mimic hypoxia
and subsequently generate reactive oxygen species (ROS) in
cultured cells and induce direct cellular injury [17, 18]. Also,
excessive generation of ROS may stimulate inflammatory
processes [18]. Previous work has shown that complexing
NAC with Co(II) seems to prevent cobalt-related toxicity in
the prostate and periprostatic tissues after injection [7] and
that C4 does not prompt excess ROS generation in human
cancer cells or normal tongue cells [19]; nevertheless, little
was known of the potential for acute or chronic systemic
toxicity from C4 in vivo. Here, we showed that a single
intramuscular injection of C4 at a concentration 10 times
than intended for clinical use, or 100 times more than what
would be released from the spontaneous rupture of 120 MRI
markers in a human prostate, led to no acute or chronic
systemic toxicity or inflammation, no microscopic damage to
brain, spinal cord, lung, heart, liver, kidney, or spleen, and
no changes in the body or organ weights or in the clinical
blood analyses. These findings suggest that C4 is not likely
to cause acute or chronic systemic toxicity when in clinical
use for prostate cancer brachytherapy.
With regard to acute local response, we did find evidence
of focal acute degeneration and necrosis of myofibers associated with acute granulomatous inflammation at the injection
site 48 hours after the i.m. injection. One review [20] showed
similar histologic findings at 48 hours after an intramuscular
injection of saline to rodents and rabbits, with evidence of
myofiber regeneration and mild fibrosis at 10 days and 42 days
after the injection. These findings are similar to observations
in our study at 28 and 63 days after the injection, and they are
also similar to those of another study involving intramuscular
injections of antibiotics in sheep [21]. We consider these
focal acute changes to be a normal, transient response to
muscle trauma at 48 hours, the extent of which was similar
to that from intramuscular injection of saline or antibiotics.
Moreover, because the encapsulated C4 will be implanted
in prostate tumors, we anticipate that this local injection
response does not have the potential to harm patients.
Our study did have limitations. Not all of the biochemical
markers that have been suggested as possible toxic indicators
were included in this study, as sometimes it is impossible
to plan for all measurements of toxicity when using small
species.

5. Conclusions
In conclusion, we showed that a single intramuscular dose
of the novel MRI-marker C4, in concentrations ranging
from 0 to 10 times the dose intended for clinical use,
produced no acute or chronic clinical systemic toxicity or
inflammation in Sprague-Dawley rats. These results suggest
that C4 may not cause acute or chronic clinical systemic
toxicity or inflammation for clinical use in brachytherapy.
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